MTOR and neoplasm: The small-molecule inhibitor SBI-0206965 selectively inhibits ULK1 and synergizes with mTOR inhibitors to promote ULK1 degradation and enhance tumor cell apoptosis, outperforming chloroquine (CQ) in efficacy [135].